Corcept Therapeutics (CORT) Inspires Confidence with ROSELLA Phase 3 Survival Data

Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the 10 best biotech stocks with highest upside potential.

On April 11, Corcept Therapeutics Inc. (NASDAQ:CORT) released the overall survival results from its Phase 3 ROSELLA study involving Lifyorli and nab-paclitaxel treatment for women with platinum-resistant ovarian cancer during the annual conference of the Society of Gynaecologic Oncology. The findings were concurrently published in The Lancet journal. The ROSELLA study achieved both of its primary objectives of overall survival and progression-free survival without compromising on safety. This backs our bullish views for the stock.

Copyright: katrintimoff / 123RF Stock Photo

The combination of Lifyorli with nab-paclitaxel is now part of the National Comprehensive Cancer Network guidelines as a preferred treatment regimen. The drug received approval from the FDA in March 2026 for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Patients receiving Lifyorli with nab-paclitaxel showed 35% fewer chances of mortality. Median overall survival was 4.1 months higher. The patients had a 30% lower rate of disease progression. The combination therapy is safe. The common adverse effects include low levels of haemoglobin, neutrophils, fatigue, nausea, diarrhea, platelets, rash, and reduced appetite.

Corcept Therapeutics Inc. (NASDAQ:CORT) is a commercial-stage pharmaceutical company that is involved in developing therapies for severe conditions. These include endocrinologic, oncologic, metabolic, and neurologic disorders. It is developing medicines that target hyperglycemia, hypercortisolism, prostate cancer, and amyotrophic lateral sclerosis.

While we acknowledge the risk and potential of CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CORT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.